Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) registered its phase 2 clinical trial application for its Xiao Chaihu granules for children, according to a Tuesday filing with the Shanghai bourse.
The drug is indicated for gastrointestinal colds or stomach flu with Shaoyang syndrome in children, the filing said.
Shares fell 1% in Hong Kong and Shanghai during late morning trading on Tuesday.